Cargando…

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia

BACKGROUND: Molecular genetic abnormalities are observed in over 90% of chronic myelomonocytic leukemia (CMML) cases. Recently, several studies have demonstrated the negative prognostic impact of ASXL1 mutations in CMML patients. We evaluated the prognostic impact of ASXL1 mutations and compared fiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyun-Young, Lee, Ki-O, Park, Silvia, Jang, Jun Ho, Jung, Chul Won, Kim, Sun-Hee, Kim, Hee-Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Laboratory Medicine 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056400/ https://www.ncbi.nlm.nih.gov/pubmed/30027691 http://dx.doi.org/10.3343/alm.2018.38.6.495

Ejemplares similares

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
por: Perez Botero, J, et al.
Publicado: (2015)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Novel Mutations in CEBPA in Korean Patients with Acute Myeloid Leukemia with a Normal Karyotype
por: Kim, Sollip, et al.
Publicado: (2012)

Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia
por: Johnson, Steven M., et al.
Publicado: (2019)

Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report
por: Deng, Lai-Jun, et al.
Publicado: (2023)

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
por: Binder, Moritz, et al.
Publicado: (2022)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA
por: Wang, Yu-Hung, et al.
Publicado: (2023)

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Binder, Moritz, et al.
Publicado: (2023)

Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Comparison of existing prognostic models in chronic myelomonocytic leukemia
por: Jian, Jin-Li, et al.
Publicado: (2020)

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
por: Duchmann, Matthieu, et al.
Publicado: (2018)

Novel splicing-factor mutations in juvenile myelomonocytic leukemia
por: Takita, J, et al.
Publicado: (2012)

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Chesnais, Virginie, et al.
Publicado: (2012)

Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
por: Nie, Yanbo, et al.
Publicado: (2022)

RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
por: Bera, Rabindranath, et al.
Publicado: (2019)

NUP98 Rearrangement in Acute Myelomonocytic Leukemia With t(11;19)(p15;p12): The First Case Report Worldwide
por: Lim, Hyeon-Ho, et al.
Publicado: (2017)

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2012)

Clinical and molecular features of CBL-mutated juvenile myelomonocytic leukemia
por: Yoshida, Taro, et al.
Publicado: (2023)

Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia
por: Sakaguchi, Hirotoshi, et al.
Publicado: (2015)

Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study
por: Choi, Yunsuk, et al.
Publicado: (2021)

Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders
por: Dussiau, Charles, et al.
Publicado: (2023)

Acute myeloid leukemia in a father and son with a germline mutation of ASXL1
por: Seiter, Karen, et al.
Publicado: (2018)

Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
por: Fan, Yi, et al.
Publicado: (2021)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation
por: Lee, Sung-Eun, et al.
Publicado: (2015)

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis
por: Shou, Li-Hong, et al.
Publicado: (2017)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia
por: Kim, Borahm, et al.
Publicado: (2020)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015)

Lysozyme nephropathy in chronic myelomonocytic leukemia
por: Patel, Ami B., et al.
Publicado: (2019)

Diagnosis and treatment of chronic myelomonocytic leukemia
por: Kwon, Jihyun
Publicado: (2021)

Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
por: Coltro, G., et al.
Publicado: (2022)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9d4iqg020mrgq62igdgmmq6lnf